Back to discover
Disease

Liver Diseases

Late-stage therapeutic developmentActively researchedSteady momentum
27
Publications
19
Clinical trials
12
Related conditions
2025
Latest publication
Current focus
Therapeutic developmentInflammation & immunityMetabolic & lifestyle factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Genetics of liver disease in adults.

Research2024-03-29Hepatology communications

Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis.

Research2023-11-19International journal of molecular sciences

Thyroid hormone action and liver disease, a complex interplay.

Research2023-08-02Hepatology (Baltimore, Md.)

Endoplasmic reticulum stress in liver diseases.

Research2022-05-24Hepatology (Baltimore, Md.)

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q3 2027.
  • 1 industry development reported.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Azathioprineapproved

Approval — Jayempi is indicated in combination with other immunosuppressive agents for the prophylax… (2021)

Clinical trials

16 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
8
Late-stage
5
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2021emaApprovalAzathioprine· Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases: severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs) auto-immune hepatitis  systemic lupus erythematosus dermatomyositis polyarteritis nodosa pemphigus vulgaris and bullous pemphigoid Behçet’s disease refractory auto-immune haemolytic anaemia, caused by warm IgG antibodies chronic refractory idiopathic thrombocytopenic purpura Jayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3 Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

27 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20122025
Most influential
Recent publications
Major themes8
  • Liver Diseases11
  • Liver2
  • Betacoronavirus1
  • Biological Specimen Banks1
  • Cardiovascular Diseases1
  • Consensus1
  • COVID-191
  • Cytokine Release Syndrome1
Leading journals6
  • International journal of molecular sciences5
  • Hepatology (Baltimore, Md.)4
  • Cellular & molecular immunology2
  • Gut2
  • Cells1
  • Diabetes care1
Leading researchers8
  • Abadía-Molina F1
  • Abecasis GR1
  • Adams DH1
  • Aggarwal R1
  • Ahmadi N1
  • Aimo A1
  • Ajoolabady A1
  • Akbar SMF1
Affiliations (unnormalised)6
  • Columbia University2
  • Mayo Clinic2
  • 2nd Department and Clinic of Paediatrics1
  • Aarhus University Hospital1
  • Addenbrooke's Hospital1
  • Bangabandhu Sheikh Mujib Medical University1

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Liver diseases are pathological processes affecting the liver. The literature grounding treats this as an umbrella category that includes acute liver injury, viral hepatitis, alcoholic liver disease, metabolic-associated fatty liver disease, liver fibrosis, and hepatocellular carcinoma.

Causes

The supplied grounding indicates that liver diseases can be caused by a variety of pathogenic factors, including viruses, alcohol, and drugs. It also supports an etiologic role for disturbances in the gut microbiota and exposure to dietary and microbial products, but does not define specific disease-by-disease causes beyond these broad categories.

Pathophysiology

The liver has a complex immunological environment in which metabolic and tissue-remodeling functions involve elements of inflammation. Disease-related mechanisms in the supplied grounding include excessive immune activation, altered macrophage polarization, and interactions with the gastrointestinal microbiome, as well as endoplasmic reticulum stress and disrupted homeostasis. These processes are described as contributing to initiation and progression of liver pathology through inflammatory and immune-mediated pathways.

Risk factors

The grounding supports exposure to viruses, alcohol, and drugs as factors associated with liver disease. It also suggests that changes in the gut microbiota and related host-microbe interactions may be associated with liver disease, but does not provide a more specific risk-factor list.

Current standard of care

The supplied grounding does not provide a disease-specific standard treatment approach for liver diseases as a whole. It only indicates that the literature covers therapy and drug therapy at a broad level, without supporting a specific modality or drug class for the umbrella category.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Pathological processes of the LIVER.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.